APVOCompany update

Mipletamig Combination: 21% of Evaluable Frontline AML Patients Proceeded to Transplant

Aptevo reported that 10 of 47 evaluable frontline AML patients treated with mipletamig plus venetoclax and azacitidine proceeded to allogeneic stem cell transplantation (21%). Nine patients came from the ongoing Phase 1b RAINIER trial and one from a completed dose expansion trial; the release also cited 3 of 286 patients (0.7%) undergoing transplantation after VEN+AZA alone in the historical VIALE-A trial and stated that cross-trial comparisons are limited. Aptevo expects RAINIER dose optimization to conclude by...

Published October 26, 2026 at 8:22 AM EDTAptevo Therapeutics Inc.SEC filing

Share this story

Key takeaways

5-7 ranked factual bullets

Key metrics

Frontline patients proceeding to allogeneic stem cell transplantation after mipletamig plus VEN+AZA

10 of 47 evaluable patients (21%)

Sources of reported transplant outcomes

9 from the ongoing Phase 1b RAINIER trial; 1 from the previously completed dose expansion trial

Historical VIALE-A transplant outcomes with VEN+AZA alone

3 of 286 patients (0.7%)

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

All APVO coverage

ICCMCompany update

IceCure shareholders approve meeting agenda after adjournment

MRVLM&A

Marvell to acquire Lumentum in all-stock transaction valued at over $275B enterprise value

AAPLEarnings

Apple reports fourth quarter results

YXTM&A

Yext Completes Acquisition of Flamel.ai

Follow APVO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert